Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v2.4.0.8
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 134,010 [1] $ 185,798 [1]
Accounts receivable, net 23,113 [1] 19,767 [1]
Inventory, net 18,334 [1] 18,079 [1]
Prepaid expenses and other current assets 7,553 [1] 19,084 [1]
Total current assets 183,010 [1] 242,728 [1]
Property, plant, equipment, and investment properties, net 17,348 [1] 17,027 [1]
Intangible assets, net 69,059 [1] 74,533 [1]
In-process research and development 793,326 [1] 793,341 [1]
Goodwill 226,001 [1] 226,373 [1]
Investments, net 33,428 [1] 30,653 [1]
Other assets 4,910 [1] 6,861 [1]
Total assets 1,327,082 [1] 1,391,516 [1]
Current liabilities:    
Accounts payable 10,041 [1] 13,414 [1]
Accrued expenses 54,964 [1] 65,874 [1]
Current portion of lines of credit and notes payable 14,397 [1] 12,562 [1]
Total current liabilities 79,402 [1] 91,850 [1]
2033 Senior Notes, net of discount and estimated fair value of embedded derivatives 116,365 [1] 211,912 [1]
Other long-term liabilities, principally contingent consideration and deferred tax liabilities 218,490 [1] 214,775 [1]
Total long-term liabilities 334,855 [1] 426,687 [1]
Total liabilities 414,257 [1] 518,537 [1]
Equity:    
Common Stock - $0.01 par value, 750,000,000 shares authorized; 427,102,876 and 414,818,195 shares issued at June 30, 2014 and December 31, 2013, respectively 4,271 [1] 4,148 [1]
Treasury Stock - 1,245,367 and 2,264,063 shares at June 30, 2014 and December 31, 2013, respectively (4,051) [1] (7,362) [1]
Additional paid-in capital 1,490,071 [1] 1,379,383 [1]
Accumulated other comprehensive income 304 [1] 3,418 [1]
Accumulated deficit (573,203) [1] (503,177) [1]
Total shareholders’ equity attributable to OPKO 917,392 [1] 876,410 [1]
Noncontrolling interests (4,567) [1] (3,431) [1]
Total shareholders’ equity 912,825 [1] 872,979 [1]
Total liabilities and equity $ 1,327,082 [1] $ 1,391,516 [1]
[1] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.